Wolfe Research Reiterates Outperform Rating on BioMarin Pharmaceutical Inc. (BMRN): 'we'd be buyer on weakness'
March 16, 2026 10:07 AM
Wolfe Research analyst Alexandria Hammond reiterated an Outperform rating and $95.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
